Advances and challenges in drug design of PPARδ ligands (2018)
- Authors:
- USP affiliated authors: WRENGER, CARSTEN - ICB ; TROSSINI, GUSTAVO HENRIQUE GOULART - FCF ; HONORIO, KÁTHIA MARIA - EACH ; KRONENBERGER, THALES - ICB
- Unidades: ICB; FCF; EACH
- DOI: 10.2174/1389450118666170414113159
- Subjects: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE; SÍNDROME X METABÓLICA; ÁCIDOS GRAXOS; DOENÇAS METABÓLICAS; PARASITOLOGIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Current Drug Targets
- ISSN: 1389-4501
- Volume/Número/Paginação/Ano: v. 19, n. 2, p. 144-154, 2018
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
MALTAROLLO, Vinícius Gonçalves et al. Advances and challenges in drug design of PPARδ ligands. Current Drug Targets, v. 19, n. 2, p. 144-154, 2018Tradução . . Disponível em: https://doi.org/10.2174/1389450118666170414113159. Acesso em: 03 out. 2024. -
APA
Maltarollo, V. G., Kronenberger, T., Windshuegel, B., Wrenger, C., Trossini, G. H. G., & Honório, K. M. (2018). Advances and challenges in drug design of PPARδ ligands. Current Drug Targets, 19( 2), 144-154. doi:10.2174/1389450118666170414113159 -
NLM
Maltarollo VG, Kronenberger T, Windshuegel B, Wrenger C, Trossini GHG, Honório KM. Advances and challenges in drug design of PPARδ ligands [Internet]. Current Drug Targets. 2018 ; 19( 2): 144-154.[citado 2024 out. 03 ] Available from: https://doi.org/10.2174/1389450118666170414113159 -
Vancouver
Maltarollo VG, Kronenberger T, Windshuegel B, Wrenger C, Trossini GHG, Honório KM. Advances and challenges in drug design of PPARδ ligands [Internet]. Current Drug Targets. 2018 ; 19( 2): 144-154.[citado 2024 out. 03 ] Available from: https://doi.org/10.2174/1389450118666170414113159 - Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure–activity relationship analyses
- Targeting the Plasmodium falciparum Plasmepsin V by ligand-based virtual screening
- On the relationship of anthranilic derivatives structure and the FXR (Farnesoid X receptor) agonist activity
- In silico studies on the interaction between bioactive ligands and ALK5, a biological target related to the cancer treatment
- Current trends in quantitative structure-activity relationship validation and applications on drug discovery
- Simulação do espectro de absorção UV do filtro solar p-metoxicinamato de etilexila empregando métodos teóricos (TD-DFT)
- Use of machine learning approaches for novel drug discovery
- Understanding PPAR-δ affinity and selectivity using hologram quantitative structure–activity modeling, molecular docking and GRID calculations
- The role of QSAR and virtual screening studies in type 2 diabetes drug discovery
- Benchmark studies of UV-vis spectra simulation for cinnamates with UV filter profile
Informações sobre o DOI: 10.2174/1389450118666170414113159 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas